Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
November 03, 2021 16:01 ET
|
Lumos Pharma, Inc.
Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sitesSix-month primary outcome data readout from OraGrowtH210 expected 2H 2023...
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
October 21, 2021 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will...
Lumos Pharma to Participate in September Investor Conferences
September 02, 2021 08:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company...
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
August 05, 2021 08:00 ET
|
Lumos Pharma, Inc.
• Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board •...
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
July 26, 2021 16:18 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach,...